New immune cells to help stem cell transplant success
Part of Immune system & allergy clinical trials.
This trial tests whether a special type of immune cell (called CD8 regulatory precursors) can help prevent the body from rejecting a stem cell transplant from a donor. It is for patients receiving a stem cell transplant from a related donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- You are planning to get a stem cell transplant from a family member (not from an unrelated donor or cord blood)
- You are willing and able to follow the study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
This trial tests a stem cell transplant using a reduced-intensity chemotherapy regimen and a low dose of a drug called cyclophosphamide after the transplant to help prevent graft-versus-host disease (GVHD), a common complication where donor cells attack the recipient's body. It is for people with certain blood cancers or bone marrow disorders who have a suitable donor.
This study tests whether special cells from your donor, called Treg cells (a type of immune cell that calms inflammation), can help treat graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have already tried other treatments but still have GVHD symptoms.
This study looks at special immune cells in the body that may be involved in graft-versus-host disease (GVHD), a complication after a stem cell transplant. The goal is to better understand these cells to improve future treatments for GVHD.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Hear when a new Graft-versus-host Disease (GVHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.